Android app Apple app link

Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial

By Yahoo! Finance   |   4 weeks ago
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial

Estrella Immunopharma, Inc. (NASDAQ:ESLA) advances EB103 therapy in STARLIGHT-1 trial, dosing second cohort for advanced B-cell NHL treatment. CEO highlights potential benefits over CAR-T. Company's pipeline offers hope for improved immunotherapies.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.